Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Skin Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Poly I-C × Gastrointestinal × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡